MGNX News and Press, MacroGenics Inc. From 11/02/21

Investigational New Drug (IND) application submitted for MGD024, a next generation DART ® molecule targeting CD123 and CD3 for AML U.S. Food & Drug Administration (FDA) approves MacroGenics’ GMP manufacturing facility to produce MARGENZA ® drug subst...

ADC, AFG, DADA, AIZ, AKAM, AMCR, AMED, AMGN, ANDE, APPS, AQST, ATVI, AWK, AYX, BFAM, BGFV, BKH, BTG, BXC, CASA, CDK, CDLX, CERS, CGBD, CHCT, CHK, CLW, COUR, CRK, [CSLT]], CVGI, CZR, DCP, DCPH, DENN, DHT, DOX, DRRX, [DVN]], EARN, EGHT, EIX, EKSO, ELVT, ENLC, EXAS, EXEL, FMC, FNF, FRG, GAIN, GN...

MacroGenics (NASDAQ:MGNX) is scheduled to announce Q3 earnings results on Tuesday, November 2nd, after market close. The consensus EPS Estimate is -$0.71 (-7.6% Y/Y) and the consensus Revenue Estimate is $34.44M (+88.7% Y/Y). Over the last 3 months, EPS estimates have seen 2 upward revisions ...

ROCKVILLE, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial...

BTIG analyst Kaveri Pohlman assumed coverage of Replimune Group (NASDAQ:REPL) with a Buy rating and $60 price target (PT), implying a premium of ~93% from last close. The analyst assumed coverage of 10 more Immuno-oncology companies, and believes "much of the most promising work" involves bro...

The smaller cap biotech space offers two key advantages for investors right now: cyclical diversification and diversification away from the vaccine monolithic theme. To break that down a bit, the stock market has been volatile over the past month, with many growth plays getting smacked down a...

Gainers: Offerpad Solutions (NYSE:OPAD) +48%. Arqit Quantum (NASDAQ:ARQQ) +36%. AEye (NASDAQ:LIDR) +36%. Rockley (NYSE:RKLY) +29%. IronNet (NYSE:IRNT) +32%. Leap Therapeutics (NASDAQ:LPTX) +27%. aTyr Pharma (NASDAQ:LIFE) +27%. Tuesday Morning Corporation (NASDAQ:TUEM) ...

Shares of MacroGenics (NASDAQ: MGNX) were tanking 26.4% lower as of 11:39 a.m. EDT on Thursday. The big decline came after the company announced data from a cohort in a phase 3 study evaluating margetuximab in combination with retifanlimab in treating gastroesophageal adenocarcinoma...

21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A 78% of patients had tumor shrinkage at first scan Median duration of response was 10.3 months as of data cuto...

Metastatic castration-resistant prostate cancer (mCRPC): 21 of 39 patients (54%) achieved ≥ 50% prostate-specific antigen (PSA) reduction; 10 of 16 (63%) RECIST-evaluable patients had anti-tumor activity; 4 of 16 (25%) achieved partial responses (two confirmed and two unconfirmed) ...